Mineralys Therapeutics – A targeted approach for the control of hypertension

A targeted
approach for the
control of
hypertension

At Mineralys Therapeutics we are focused on developing medicines to target diseases driven by abnormally elevated aldosterone.

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone.

Hypertension has resulted in an estimated average of $130 billion annual economic burden in the United States alone between 2003 and 2014

Controlling hypertension is critical to reducing cardiovascular and renal disease; yet over 30 million hypertensive patients in the United States are unable to achieve their BP goal despite treatment.

Recent studies have demonstrated that elevated aldosterone production is prevalent in over 25% of all hypertensive patients.

Elevated aldosterone levels drive blood volume and blood pressure while also causing inflammatory and fibrotic increases leading to higher risk of stroke, kidney damage and heart failure.

By normalizing aldosterone levels, we believe lorundrostat can provide an effective and more targeted approach for the control of hypertension.

THE SOLUTION

Targeting the underlying cause of hypertension

Lorundrostat is a highly selective aldosterone synthase inhibitor developed to address abnormally elevated aldosterone, an underlying cause prevalent in at least 25% of all hypertensive patients.

Lorundrostat has demonstrated selectivity for the reduction of aldosterone with no cortisol suppression. Lorundrostat selectivity holds the potential for targeted treatment of blood pressure in hypertension patients with abnormally elevated aldosterone

Lorundrostat has demonstrated compelling clinical results, and once-daily dosing flexibility and was well tolerated profile in a recently completed phase 2 clinical trial.

Hypertension has resulted in an estimated average of $130 billion annual economic burden in the United States alone between 2003 and 2014

THE SOLUTION

Targeting the underlying cause of hypertension

© 2023 Mineralys Therapeutics, Inc.